ArticleFrontiers in pharmacology2019
The Off-Label Use of Antineoplastics in Oncology Is Limited But Has Notable Scientific Support in a University Hospital Setting.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Cephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action.BMC cancer · 2025Article
- Off-label use of sodium cantharidinate and vitamin B6 injection in cancer: a protocol for a systematic review and meta-analysis.Systematic reviews · 2025Article
- Paediatric off-label use of drugs in Gansu, China: a multicentre cross-sectional study.BMJ open · 2024Article
- Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients.Cell reports. Medicine · 2024Article
- Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.Journal of cancer research and clinical oncology · 2023Article
- Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution.Cancer medicine · 2023Article
- Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.ESMO open · 2023Review
- Article
- Off-Label, but on-Evidence? A Review of the Level of Evidence for Pediatric Pharmacotherapy.Clinical pharmacology and therapeutics · 2022Review
- Characteristics and survival of patients with cancer with intended off-label use-a cohort study.BMJ open · 2022Article
- Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.JAMA network open · 2021Article
- Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System.Frontiers in pharmacology · 2021Article
- Off-Label Use of Antineoplastic Drugs to Treat Malignancies: Evidence From China Based on a Nationwide Medical Insurance Data Analysis.Frontiers in pharmacology · 2021Article
- Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.